Literature DB >> 29359407

The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition.

Maureen Bardet1, Adeline Unterreiner1, Claire Malinverni1, Frédérique Lafossas1, Corinne Vedrine1, Danielle Boesch1, Yeter Kolb1, Daniel Kaiser1, Anton Glück1, Martin A Schneider1, Andreas Katopodis1, Martin Renatus1, Oliver Simic1, Achim Schlapbach1, Jean Quancard1, Catherine H Régnier1, Guido Bold1, Carole Pissot-Soldermann1, José M Carballido1, Jiri Kovarik1, Thomas Calzascia1, Frédéric Bornancin1.   

Abstract

Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is essential for immune responses triggered by antigen receptors but the contribution of its paracaspase activity is not fully understood. Here, we studied how MALT1 proteolytic function regulates T-cell activation and fate after engagement of the T-cell receptor pathway. We show that MLT-827, a potent and selective MALT1 paracaspase inhibitor, does not prevent the initial phase of T-cell activation, in contrast to the pan-protein kinase C inhibitor AEB071. However, MLT-827 strongly impacted cell expansion after activation. We demonstrate this is the consequence of profound inhibition of IL-2 production as well as reduced expression of the IL-2 receptor alpha subunit (CD25), resulting from defective canonical NF-κB activation and accelerated mRNA turnover mechanisms. Accordingly, MLT-827 revealed a unique transcriptional fingerprint of MALT1 protease activity, providing evidence for broad control of T-cell signaling pathways. Altogether, this first report with a potent and selective inhibitor elucidates how MALT1 paracaspase activity integrates several T-cell activation pathways and indirectly controls gamma-chain receptor dependent survival, to impact on T-cell expansion.
© 2017 Australasian Society for Immunology Inc.

Entities:  

Keywords:  Interleukin‐2; MALT1 paracaspase; NF‐kappaB; T‐cell receptor; T‐cell survival; protease inhibitor; signal transduction

Mesh:

Substances:

Year:  2017        PMID: 29359407     DOI: 10.1111/imcb.1018

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  20 in total

1.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

2.  Inhibition of MALT1 Decreases Neuroinflammation and Pathogenicity of Virulent Rabies Virus in Mice.

Authors:  S Van Gucht; R Beyaert; E Kip; J Staal; H G Tima; L Verstrepen; M Romano; K Lemeire; V Suin; A Hamouda; M Baens; C Libert; M Kalai
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

3.  Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.

Authors:  Yong Li; Shengping Huang; Xuan Huang; Xiuzhen Li; Adrian Falcon; Adele Soutar; Frederic Bornancin; Zhisheng Jiang; Hong-Bo Xin; Mingui Fu
Journal:  Cell Signal       Date:  2018-06-18       Impact factor: 4.315

4.  MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.

Authors:  Jia-Ying Lloyd Lee; Prasanna Ekambaram; Neil M Carleton; Dong Hu; Linda R Klei; Zongyou Cai; Max I Myers; Nathaniel E Hubel; Lidija Covic; Sameer Agnihotri; Daniel Krappmann; Frédéric Bornancin; Adrian V Lee; Steffi Oesterreich; Linda M McAllister-Lucas; Peter C Lucas
Journal:  Mol Cancer Res       Date:  2022-03-01       Impact factor: 6.333

5.  Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell-Mediated Autoimmunity.

Authors:  Kea Martin; Ratiba Touil; Yeter Kolb; Grozdan Cvijetic; Kiichi Murakami; Laura Israel; Fernanda Duraes; David Buffet; Anton Glück; Satoru Niwa; Marc Bigaud; Tobias Junt; Natasa Zamurovic; Philip Smith; Kathy D McCoy; Pamela S Ohashi; Frédéric Bornancin; Thomas Calzascia
Journal:  J Immunol       Date:  2019-10-28       Impact factor: 5.422

6.  MALT1 targeting suppresses CARD14-induced psoriatic dermatitis in mice.

Authors:  Inna S Afonina; Rudi Beyaert; Elien Van Nuffel; Jens Staal; Griet Baudelet; Mira Haegman; Yasmine Driege; Tino Hochepied
Journal:  EMBO Rep       Date:  2020-04-28       Impact factor: 8.807

Review 7.  Impaired Control of Epstein-Barr Virus Infection in B-Cell Expansion with NF-κB and T-Cell Anergy Disease.

Authors:  Swadhinya Arjunaraja; Pamela Angelus; Helen C Su; Andrew L Snow
Journal:  Front Immunol       Date:  2018-02-08       Impact factor: 7.561

Review 8.  The CBM-opathies-A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex.

Authors:  Henry Y Lu; Bradly M Bauman; Swadhinya Arjunaraja; Batsukh Dorjbal; Joshua D Milner; Andrew L Snow; Stuart E Turvey
Journal:  Front Immunol       Date:  2018-09-19       Impact factor: 7.561

Review 9.  NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.

Authors:  Paula Grondona; Philip Bucher; Klaus Schulze-Osthoff; Stephan Hailfinger; Anja Schmitt
Journal:  Biomedicines       Date:  2018-03-26

10.  Molecular architecture and regulation of BCL10-MALT1 filaments.

Authors:  Florian Schlauderer; Thomas Seeholzer; Ambroise Desfosses; Torben Gehring; Mike Strauss; Karl-Peter Hopfner; Irina Gutsche; Daniel Krappmann; Katja Lammens
Journal:  Nat Commun       Date:  2018-10-02       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.